Caroline A Heckman

List of Publications by Year in Descending Order

131 papers	**3,321** citations	**25** h-index	**57** g-index
147 ext. papers	**4,034** ext. citations	**5.5** avg, IF	**4.75** L-index

#	Paper	IF	Citations
131	The Peptide-Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death.. *HemaSphere*, **2022**, 6, e687	0.3	1
130	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia.. *HemaSphere*, **2022**, 6, e701	0.3	0
129	Bipartite network models to design combination therapies in acute myeloid leukaemia.. *Nature Communications*, **2022**, 13, 2128	17.4	1
128	Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches. *Proteomes*, **2021**, 9,	4.6	1
127	Deep Immune Profiling in Multiple Myeloma at Diagnosis and Under Lenalidomide Maintenance Therapy. *Blood*, **2021**, 138, 1597-1597	2.2	
126	Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. *Blood*, **2021**, 138, 608-608	2.2	
125	Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds. *Blood*, **2021**, 138, 3356-3356	2.2	1
124	Single Cell RNA Sequencing Identifies Potential Molecular Indicators of Response to Melflufen in Multiple Myeloma. *Blood*, **2021**, 138, 1194-1194	2.2	
123	Ex Vivo Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial. *Blood*, **2021**, 138, 228-228	2.2	
122	Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. *Blood*, **2021**, 138, 3438-3438	2.2	
121	Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation. *Blood*, **2021**, 138, 4041-4041	2.2	0
120	Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform. *Blood*, **2021**, 138, 2666-2666	2.2	
119	Implementing a functional precision medicine tumor board for acute myeloid leukemia. *Cancer Discovery*, **2021**,	24.4	8
118	Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. *Leukemia*, **2021**, 35, 1964-1975	10.7	6
117	Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma. *Cancers*, **2021**, 13,	6.6	1
116	Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. *Cancers*, **2021**, 13,	6.6	12
115	Fusion gene detection by RNA sequencing complements diagnostics of acute myeloid leukemia and identifies recurring NRIP1-MIR99AHG rearrangements. *Haematologica*, **2021**,	6.6	3

#	Title	IF	Cit.
114	Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients. *Scientific Reports*, **2021**, 11, 12866	4.9	1
113	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. *Npj Precision Oncology*, **2021**, 5, 71	9.8	0
112	RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. *Leukemia*, **2021**, 35, 1087-1099	10.7	13
111	Prognostic significance of esterase gene expression in multiple myeloma. *British Journal of Cancer*, **2021**, 124, 1428-1436	8.7	7
110	Endogenous and combination retinoids are active in myelomonocytic leukemias. *Haematologica*, **2021**, 106, 1008-1021	6.6	2
109	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. *Science Advances*, **2021**, 7,	14.3	8
108	S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 723016	5.7	2
107	Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. *Blood Advances*, **2021**, 5, 4125-4139	7.8	0
106	FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. *Scientific Reports*, **2021**, 11, 23565	4.9	0
105	MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. *Journal of Hematology and Oncology*, **2020**, 13, 173	22.4	26
104	Immunogenomic Landscape of Hematological Malignancies. *Cancer Cell*, **2020**, 38, 380-399.e13	24.3	37
103	Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. *Leukemia*, **2020**, 34, 3186-3196	10.7	9
102	Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. *Cancers*, **2020**, 12,	6.6	4
101	Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia. *Blood*, **2020**, 136, 39-40	2.2	
100	A candid view of CANDOR. *Lancet, The*, **2020**, 396, 147-148	40	
99	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. *Leukemia*, **2020**, 34, 2780-2784	10.7	2
98	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. *Haematologica*, **2020**, 105, 1527-1538	6.6	8
97	Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. *Blood Advances*, **2020**, 4, 546-559	7.8	21

96	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. *Haematologica*, **2020**, 105, 708-720	6.6	40
95	Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. *Leukemia*, **2019**, 33, 2548-2553	10.7	8
94	Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. *PLoS Computational Biology*, **2019**, 15, e1006752	5	53
93	Making Sense of the Epigenome Using Data Integration Approaches. *Frontiers in Pharmacology*, **2019**, 10, 126	5.6	35
92	Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. *Cancer Research*, **2019**, 79, 2466-2479	10.1	14
91	Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia. *Scientific Reports*, **2019**, 9, 11796	4.9	9
90	In Vitro and inVivo Activity of Melflufen in Amyloidosis. *Blood*, **2019**, 134, 3100-3100	2.2	2
89	Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma. *Blood*, **2019**, 134, 3069-3069	2.2	
88	Germline Gene Aberrations Are Common in High-Risk Adult and Pediatric Acute Lymphoblastic Leukemia Patients. *Blood*, **2019**, 134, 1472-1472	2.2	
87	Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling. *Blood*, **2019**, 134, 1280-1280	2.2	
86	Combined gene essentiality scoring improves the prediction of cancer dependency maps. *EBioMedicine*, **2019**, 50, 67-80	8.8	10
85	Dasatinib and navitoclax act synergistically to target NUP98-NSD1/FLT3-ITD acute myeloid leukemia. *Leukemia*, **2019**, 33, 1360-1372	10.7	21
84	Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. *Oncogene*, **2019**, 38, 3288-3300	9.2	27
83	Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 3002-3005	1.9	
82	Germline alterations in a consecutive series of acute myeloid leukemia. *Leukemia*, **2018**, 32, 2282-2285	10.7	14
81	A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. *SLAS Discovery*, **2018**, 23, 687-696	3.4	9
80	RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities. *Blood*, **2018**, 132, 4257-4257	2.2	3
79	Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. *Blood*, **2018**, 132, 2763-2763	2.2	1

No.	Reference	IF	Cit.
78	A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines. *Blood*, **2018**, 132, 1975-1975	2.2	1
77	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. *Blood*, **2018**, 132, 264-264	2.2	1
76	Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity. *Blood*, **2018**, 132, 2210-2210	2.2	2
75	Predictive Response Biomarkers for BET Inhibitors in AML. *Blood*, **2018**, 132, 2749-2749	2.2	0
74	Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9. *Blood*, **2018**, 132, 2634-2634	2.2	1
73	Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing Allows Identification of Physiologically Distinct Sub-Clones That Can Inform Therapeutic and Drug Development Strategies. *Blood*, **2018**, 132, 1901-1901	2.2	
72	Eltrombopag Promotes Megakaryocyte Survival and Signaling in the Presence of Specific Cytotoxic Agents. *Blood*, **2018**, 132, 3836-3836	2.2	
71	Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo. *Blood*, **2018**, 132, 3975-3975	2.2	
70	Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 725-732	1.9	4
69	Improving genomics-based predictions for precision medicine through active elicitation of expert knowledge. *Bioinformatics*, **2018**, 34, i395-i403	7.2	3
68	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. *European Urology*, **2017**, 71, 319-327	10.2	50
67	Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry. *Human Mutation*, **2017**, 38, 269-274	4.7	11
66	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. *Blood*, **2017**, 130, 789-802	2.2	63
65	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. *Blood Advances*, **2017**, 1, 2257-2268	7.8	17
64	The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. *BMC Genomics*, **2017**, 18, 629	4.5	29
63	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. *Blood*, **2017**, 130, 854-854	2.2	1
62	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. *Oncotarget*, **2017**, 8, 22606-22615	3.3	8
61	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. *Oncotarget*, **2017**, 8, 56338-56350	3.3	25

60	The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. *Oncotarget*, **2017**, 8, 103731-103743	3.3	16
59	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. *Oncotarget*, **2017**, 8, 97516-97527	3.3	16
58	In Silico and Ex Vivo Drug Screening Identifies Dasatinib as a Potential Targeted Therapy for T-ALL. *Blood*, **2016**, 128, 4029-4029	2.2	
57	Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML. *Blood*, **2016**, 128, 4711-4711	2.2	
56	Simultaneous Monitoring of Drug Responses on Distinct Hematopoietic Cell Populations Allow Assessment of Direct and Indirect Cytotoxic Effects of Targeted Therapies. *Blood*, **2016**, 128, 3515-3515	2.2	
55	A High-Throughput Biology Approach to Identify Novel Therapies Specifically Targeting AML Blasts and Leukemic Stem Cells. *Blood*, **2016**, 128, 2755-2755	2.2	
54	Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia. *Blood*, **2016**, 128, 1924-1924	2.2	
53	Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments. *Blood*, **2016**, 128, 4077-4077	2.2	
52	Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist Venetoclax in Acute Myeloid Leukemia. *Blood*, **2016**, 128, 32-32	2.2	
51	DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors. *Blood*, **2016**, 128, 198-198	2.2	
50	Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease. *Blood*, **2015**, 126, 3006-3006	2.2	
49	BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. *Blood*, **2015**, 126, 2462-2462	2.2	
48	JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. *Blood*, **2015**, 126, 867-867	2.2	
47	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. *Scientific Reports*, **2014**, 4, 5193	4.9	150
46	Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia. *Proteomics*, **2014**, 14, 2443-53	4.8	7
45	Landscape of Mutations in Relapsed Acute Myeloid Leukemia. *Blood*, **2014**, 124, 2367-2367	2.2	1
44	Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. *Blood*, **2014**, 124, 917-917	2.2	
43	Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling. *Blood*, **2014**, 124, 2160-2160	2.2	

#	Title	IF	Citations
42	Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. *Blood*, **2014**, 124, 3505-3505	2.2	
41	The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. *Blood*, **2014**, 124, 2203-2203	2.2	
40	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. *Blood*, **2014**, 124, 2046-2046	2.2	
39	Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma. *Blood*, **2014**, 124, 646-646	2.2	
38	Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse. *Blood*, **2014**, 124, 1022-1022	2.2	
37	Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies. *Blood*, **2014**, 124, 1771-1771	2.2	
36	AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. *Blood*, **2014**, 124, 2163-2163	2.2	
35	A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. *Blood*, **2014**, 124, 3139-3139	2.2	
34	Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response. *Blood*, **2014**, 124, 3351-3351	2.2	
33	Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. *Cancer Discovery*, **2013**, 3, 1416-29	24.4	247
32	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. *Blood*, **2013**, 121, 4541-50	10.2	204
31	Novel Activating STAT5B Mutations As Drivers Of T-ALL. *Blood*, **2013**, 122, 3863-3863	2.2	1
30	Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. *Blood*, **2013**, 122, 1668-1668	2.2	
29	Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. *Blood*, **2013**, 122, 3828-3828	2.2	
28	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. *Blood*, **2013**, 122, 482-482	2.2	
27	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. *Blood*, **2013**, 122, 2719-2719	2.2	
26	Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients. *Experimental Hematology*, **2012**, 40, 705-714.e3	3.1	15
25	Somatic STAT3 mutations in large granular lymphocytic leukemia. *New England Journal of Medicine*, **2012**, 366, 1905-13	59.2	535

24	Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia. *Blood*, **2012**, 120, 871-871	2.2	2
23	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. *Blood*, **2012**, 120, 288-288	2.2	1
22	Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia. *Blood*, **2012**, 120, 1302-1302	2.2	
21	Comparison of solution-based exome capture methods for next generation sequencing. *Genome Biology*, **2011**, 12, R94	18.3	215
20	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. *Blood*, **2011**, 118, 2487-2487	2.2	
19	Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. *Blood*, **2011**, 118, 936-936	2.2	
18	Phosphoprotein Profiling Predicts Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients. *Blood*, **2011**, 118, 4427-4427	2.2	
17	Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. *Genes Chromosomes and Cancer*, **2010**, 49, 1062-9	5	161
16	Functional analysis of FLT4 mutations associated with Nonne-Milroy lymphedema. *Journal of Investigative Dermatology*, **2009**, 129, 509-12	4.3	4
15	Molecular Targeting of Lymphangiogenesis and Tumor Metastasis **2009**, 283-295		
14	The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. *Cancer Research*, **2008**, 68, 4754-62	10.1	96
13	Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. *FASEB Journal*, **2006**, 20, 1462-72	6.9	237
12	Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. *Molecular and Cellular Biology*, **2005**, 25, 1608-19	4.8	210
11	CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50. *Molecular Cancer Research*, **2005**, 3, 585-96	6.6	44
10	C/EBP and C/EBP Myeloid Oncoproteins Induce Bcl-2 Via Interaction of Their Basic Regions with NF-B p50.. *Blood*, **2005**, 106, 2992-2992	2.2	
9	HDAC2 Plays a Role in Protecting t(14;18) Lymphoma Cells from Apoptosis by Up-Regulation of Bcl-2.. *Blood*, **2004**, 104, 1133-1133	2.2	
8	C/EBP and C/EBP Myeloid Oncoproteins Inhibit Apoptosis and Induce Bcl-2 Via DNA-Binding Dependent and Independent Mechanisms.. *Blood*, **2004**, 104, 2561-2561	2.2	
7	Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. *Oncogene*, **2003**, 22, 7891-9	9.2	36

6	Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. *Cancer Research*, **2003**, 63, 6666-73	10.1	20
5	NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. *Oncogene*, **2002**, 21, 3898-908	9.2	161
4	Allele-specific analysis of transcription factors binding to promoter regions. *Methods*, **2002**, 26, 19-26	4.6	3
3	Negative regulation of bcl-2 expression by p53 in hematopoietic cells. *Oncogene*, **2001**, 20, 240-51	9.2	190
2	A-Myb up-regulates Bcl-2 through a Cdx binding site in t(14;18) lymphoma cells. *Journal of Biological Chemistry*, **2000**, 275, 6499-508	5.4	48
1	The WT1 protein is a negative regulator of the normal bcl-2 allele in t(14;18) lymphomas. *Journal of Biological Chemistry*, **1997**, 272, 19609-14	5.4	62